Vectura Group, a British pharmaceutical company focused on inhaled medicines, said on Wednesday it had agreed a $1.36bn takeover by global investment firm The Carlyle Group.
Shareholders will receive 136 pence in cash plus a dividend of 19 pence for each share under the terms of the offer, representing a 32% premium on the ex-dividend closing price of the stock on Tuesday, Vectura said.
Vectura’s Chairman Bruno Angelici said the company had made strong progress since embarking on a strategy in 2019 to become a leading inhalation-focused CDMO, or contract development and manufacturing organisation.
He said that while the board remained confident in the fundamentals of the group and its strategy, the “attractive offer” secured future value for shareholders in cash today.
Vectura has 13 key inhaled and 11 non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development.
Its partners include Novartis, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.
Source: Reuters
Can’t stop reading? Read more
I Squared Weighs Stake Sale in $1bn India’s Think Gas
I Squared Capital is considering selling a minority stake in Think Gas Distribution Pvt. that...
Ares Faces Its Biggest Decision Yet: Stick With Private Credit or Become an Alts Supermarket
Ares Management Corp. faces the sort of quandary that other financial firms might find enviable....
What Does Private Equity See in Football?
It’s easy to understand why super-wealthy individuals or oil-rich nations might want to buy...